Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human ARID1A Antibodies:
anti-Mouse (Murine) ARID1A Antibodies:
anti-Rat (Rattus) ARID1A Antibodies:
Go to our pre-filtered search.
Human Polyclonal ARID1A Primary Antibody for ICC, IF - ABIN4281563
Bolander, Agnarsdóttir, Strömberg, Ponten, Hesselius, Uhlen, Bergqvist: The protein expression of TRP-1 and galectin-1 in cutaneous malignant melanomas. in Cancer genomics & proteomics 2009
Show all 21 Pubmed References
Human Polyclonal ARID1A Primary Antibody for WB - ABIN188644
Wurster, Precht, Pazin: NF-κB and BRG1 bind a distal regulatory element in the IL-3/GM-CSF locus. in Molecular immunology 2011
BAF250a loss in AE is consistently associated with the development of BAF250a-negative endometriosis-associated cancers and appears to be an early event in most of these cases.
Transcriptome analysis revealed ARID1A knockdown led to miR (show MLXIP Antibodies)-503 upregulation. CDKN2A (show CDKN2A Antibodies) was identified as a target of miR (show MLXIP Antibodies)-503, which contributes to cell senescence. Thus, the data suggests that ARID1A deficiency promote KRAS(G12D)-driven pancreatic tumorigenesis through miR (show MLXIP Antibodies)-503/CDKN2A (show CDKN2A Antibodies)-mediated senescence.
ARID1A may be a primary driver of carcinogenesis in a subset of esophageal adenocarcinomas
ARID1A mutation inactivates the apoptosis-promoting function of p53 (show TP53 Antibodies) by upregulating HDAC6 (show HDAC6 Antibodies), indicating that pharmacological inhibition of HDAC6 (show HDAC6 Antibodies) is a therapeutic strategy for ARID1A-mutated cancers.
ARID1A mutation can be an early stage event in the oncogenic transformation of endometriosis cells giving rise to ovarian clear cell carcinoma.
ARID1A expression is significantly decreased in higher stages of urothelial carcinoma and its aggressive variants.
Our data suggests that deficiency or loss of functional mutations of ARID1A in HCC (show FAM126A Antibodies) cells might contribute to the increased activity of certain cancer-promoting lncRNAs.
ARID1A loss lacks prognostic significance in early stage colorectal adenocarcinoma.
ARID1A may play an important role in the early events of gastric carcinogenesis.
loss of ARID1A is more common in advanced GC and is related to EBV positivity and MMR (show MRC1 Antibodies) deficiency
Mice with liver-specific homozygous or heterozygous Arid1a loss were resistant to tumor initiation while ARID1A overexpression accelerated initiation.
Loss of HDAC (show HDAC3 Antibodies)-mediated repression and gain of NF-kappaB (show NFKB1 Antibodies) activation underlie cytokine induction in ARID1A- and PIK3CA (show PIK3CA Antibodies)-mutation-driven ovarian cancer.
ARID1A normally targets SWI (show SMARCA1 Antibodies)/SNF (show SNRPA Antibodies) complexes to enhancers.
Consistent with the latter, Arid1a reexpression in tumor cells led to increased p21 (Cdkn1a (show CDKN1A Antibodies)) expression and dramatic accumulation of cells in G2 phase of the cell cycle. These results also indicate a potential opportunity for therapeutic intervention in ARID1A-deficient human breast cancer subtypes that retain one intact copy of the gene and also maintain wild-type TRP53 (show TP53 Antibodies) activity
The Arid1a loss reprograms chromatin to restrict promoter access by transcription factors such as C/ebpalpha (show CEBPA Antibodies), which enforces differentiation, and E2F4 (show E2F4 Antibodies), which suppresses cell-cycle re-entry.
This study provides an alternative mechanism by which Arid1a deficiency contributes to hepatocellular carcinoma tumorigenesis.
ARID1A positively regulates Klf15 expression with PGR (show PGR Antibodies) to inhibit epithelial proliferation at peri (show POSTN Antibodies)-implantation. Our results suggest that Arid1a has a critical role in modulating epithelial proliferation which is a critical requisite for fertility
Our results indicate that the Arid1a tumour suppressor gene has a key role in regulating ovarian endometrioid carcinoma differentiation
ARID1A and PIK3CA (show PIK3CA Antibodies) mutations cooperate to promote tumour growth through sustained IL-6 (show IL6 Antibodies) overproduction.
This gene encodes a member of the SWI/SNF family, whose members have helicase and ATPase activities and are thought to regulate transcription of certain genes by altering the chromatin structure around those genes. The encoded protein is part of the large ATP-dependent chromatin remodeling complex SNF/SWI, which is required for transcriptional activation of genes normally repressed by chromatin. It possesses at least two conserved domains that could be important for its function. First, it has a DNA-binding domain that can specifically bind an AT-rich DNA sequence known to be recognized by a SNF/SWI complex at the beta-globin locus. Second, the C-terminus of the protein can stimulate glucocorticoid receptor-dependent transcriptional activation. It is thought that the protein encoded by this gene confers specificity to the SNF/SWI complex and may recruit the complex to its targets through either protein-DNA or protein-protein interactions. Two transcript variants encoding different isoforms have been found for this gene.
ARID domain-containing protein 1A
, AT-rich interactive domain-containing protein 1A
, BRG1-associated factor 250a
, OSA1 nuclear protein
, SWI-like protein
, SWI/SNF complex protein p270
, SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin subfamily F member 1
, brain protein 120
, chromatin remodeling factor p250
, osa homolog 1
, AT rich interactive domain 1A (Swi1 like)
, BRG1-associated factor 250
, SWI-SNF complex protein p270
, SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily f, member 1
, Swi1 like
, AT rich interactive domain 1A (SWI-like)
, AT-rich interactive domain-containing protein 1A-like